Safety and Preliminary Efficacy of a Metabolically Armed Chimeric Antigen Receptor T Cell Therapy Targeting EGFRvIII for Recurrent Glioblastoma
Clinical trial NCT07244666 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07244666
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Status
- NOT_YET_RECRUITING
- Phase
- Early Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2025-11-15
- Primary completion
- 2027-12-31
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.